Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database.
about
Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studiesThe current role of thiazolidinediones in diabetes management.Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes: A retrospective cohort studyDipeptidyl Peptidase-4 Inhibitor Alarms: Is Heart Failure Caused by a Class Effect?Letter: Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database (Diabetes Metab J 2015;39:247-52).Response: Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database (Diabetes Metab J 2015;39:247-52).Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes.Alternative Interventions to Prevent Oxidative Damage following Ischemia/ReperfusionLessons learned from cardiovascular outcome clinical trials with dipeptidyl peptidase 4 (DPP-4) inhibitors.Resistance exercise improves cardiac function and mitochondrial efficiency in diabetic rat hearts.Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea.Pioglitazone Induces Cardiomyocyte Apoptosis and Inhibits Cardiomyocyte Hypertrophy Via VEGFR-2 Signaling Pathway
P2860
Q26765047-D34BDD06-D187-4093-B1D2-EE86581FD4F3Q30250347-A074C763-9E36-4CFB-B896-E9F896CF7375Q33833732-8CEE4181-B09B-484F-81CC-9F7099C4D247Q35790625-420090D7-ACDB-40D1-8C5D-1D12B4F01204Q35976501-CF378D1A-2743-43FB-A26F-82AA99385DB9Q35976506-40AAFC8E-AEBE-479B-BE73-FBCBCB60A3FDQ36302662-02EB2117-A847-413A-9AB6-BC3108B5A7B8Q37578724-6F72D4BE-EC93-4AB8-B61F-C3C85D38628AQ38649250-C0A7FC47-FEB4-4BAC-BE7E-55FC10FE03F4Q46285400-22AB64F7-D895-4593-B8D4-1052B5060713Q54993721-A10B2FB2-1684-4CF8-9C40-77B2D204C22CQ58804870-645301C7-3088-46FE-99C4-5CA7633A6FAA
P2860
Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Increased Risk of Hospitalizat ...... lth Insurance Claims Database.
@ast
Increased Risk of Hospitalizat ...... lth Insurance Claims Database.
@en
type
label
Increased Risk of Hospitalizat ...... lth Insurance Claims Database.
@ast
Increased Risk of Hospitalizat ...... lth Insurance Claims Database.
@en
prefLabel
Increased Risk of Hospitalizat ...... lth Insurance Claims Database.
@ast
Increased Risk of Hospitalizat ...... lth Insurance Claims Database.
@en
P2093
P2860
P1476
Increased Risk of Hospitalizat ...... lth Insurance Claims Database.
@en
P2093
Byung-Wan Lee
Chang Hee Jung
Jae Hyeon Kim
Mee-Kyoung Kim
Sang-Man Jin
You-Cheol Hwang
P2860
P304
P356
10.4093/DMJ.2015.39.3.247
P577
2015-04-22T00:00:00Z